Recommendations for streamlining precision medicine in breast cancer care in Latin America

被引:5
作者
Alvarado-Cabrero, Isabel [1 ]
Doimi, Franco [2 ]
Ortega, Virginia [3 ]
Oliveira Lima, Jurema Telles [4 ]
Torres, Ruben [5 ]
Torregrosa, Lilian [6 ]
机构
[1] Mexican Oncol Hosp, IMSS, Dept Pathol, Av Cuauhtemoc 330, Mexico City 06720, DF, Mexico
[2] Oncosalud AUNA, Dept Pathol, Lima, Peru
[3] Diagnost SRL, Dept Pathol, Montevideo, Uruguay
[4] Inst Materno Infantil Pernambuco, Dept Pathol, Recife, PE, Brazil
[5] PAHO Uruguay, Montevideo, Uruguay
[6] Pontificia Univ Javeriana, Dept Breast & Soft Tissue Surg, Bogota, Colombia
关键词
breast cancer; CDx; companion diagnostics; Latin America; precision medicine; MIDDLE-INCOME COUNTRIES; COMPANION DIAGNOSTICS; CLINICAL ONCOLOGY/COLLEGE; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; GLOBAL BURDEN; CHEMOTHERAPY; TRASTUZUMAB; AMPLIFICATION;
D O I
10.1002/cnr2.1400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The incidence of breast cancer (BC) in LMICs has increased by more than 20% within the last decade. In areas such as Latin America (LA), addressing BC at national levels evoke discussions surrounding fragmented care, limited resources, and regulatory barriers. Precision Medicine (PM), specifically companion diagnostics (CDx), links disease diagnosis and treatment for better patient outcomes. Thus, its application may aid in overcoming these barriers. Recent findings A panel of LA experts in fields related to BC and PM were provided with a series of relevant questions to address prior to a multi-day conference. Within this conference, each narrative was edited by the entire group, through numerous rounds of discussion until a consensus was achieved. The panel proposes specific, realistic recommendations for implementing CDx in BC in LA and other LMIC regions. In these recommendations, the authors strived to address all barriers to the widespread use and access mentioned previously within this manuscript. Conclusion This manuscript provides a review of the current state of CDx for BC in LA. Of most importance, the panel proposes practical and actionable recommendations for the implementation of CDx throughout the Region in order to identify the right patient at the right time for the right treatment.
引用
收藏
页数:10
相关论文
共 62 条
  • [1] Bureaucratic Itineraries in Colombia. A theoretical and methodological tool to assess managed-care health care systems
    Abadia, Cesar Ernesto
    Oviedo, Diana G.
    [J]. SOCIAL SCIENCE & MEDICINE, 2009, 68 (06) : 1153 - 1160
  • [2] Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update
    Allison, Kimberly H.
    Hammond, M. Elizabeth H.
    Dowsett, Mitchell
    McKernin, Shannon E.
    Carey, Lisa A.
    Fitzgibbons, Patrick L.
    Hayes, Daniel F.
    Lakhani, Sunil R.
    Chavez-MacGregor, Mariana
    Perlmutter, Jane
    Perou, Charles M.
    Regan, Meredith M.
    Rimm, David L.
    Symmans, W. Fraser
    Torlakovic, Emina E.
    Varella, Leticia
    Viale, Giuseppe
    Weisberg, Tracey F.
    McShane, Lisa M.
    Wolff, Antonio C.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (05) : 545 - 563
  • [3] Amadou A, 2014, SALUD PUBLICA MEXICO, V56, P547
  • [4] Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010
    Anderson, Benjamin O.
    Cazap, Eduardo
    El Saghir, Nagi S.
    Yip, Cheng-Har
    Khaled, Hussein M.
    Otero, Isabel V.
    Adebamowo, Clement A.
    Badwe, Rajendra A.
    Harford, Joe B.
    [J]. LANCET ONCOLOGY, 2011, 12 (04) : 387 - 398
  • [5] [Anonymous], 2008, Cancer control: knowledge into action. Diagnosis and treatment
  • [6] HER-2 intratumoral heterogeneity
    Arena, Vincenzo
    Pennacchia, Ilaria
    Vecchio, Fabio Maria
    Carbone, Arnaldo
    [J]. MODERN PATHOLOGY, 2013, 26 (04) : 607 - 609
  • [7] Barrios E., 2020, ATLAS INCIDENCIA C N
  • [8] Bartsch R, 2007, BIOL-TARGETS THER, V1, P19
  • [9] Delays and Barriers to Cancer Care in Low- and Middle-Income Countries: A Systematic Review
    Brand, Nathan R.
    Qui, Lang G.
    Chao, Ann
    Ilbawi, Andre M.
    [J]. ONCOLOGIST, 2019, 24 (12) : E1371 - E1380
  • [10] Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
    Cai, Lifen
    Tong, Yiwei
    Zhu, Xiaoping
    Shen, Kunwei
    Zhu, Juanying
    Chen, Xiaosong
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)